“Clostridium Difficile Infections Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Clostridium Difficile Infections Market.
The Clostridium Difficile Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Clostridium Difficile Infections Pipeline Report:
Companies across the globe are diligently working toward developing novel Clostridium Difficile Infections treatment therapies with a considerable amount of success over the years.
Clostridium Difficile Infections companies working in the treatment market are Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others, are developing therapies for the Clostridium Difficile Infections treatment
Emerging Clostridium Difficile Infections therapies in the different phases of clinical trials are- ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others are expected to have a significant impact on the Clostridium Difficile Infections market in the coming years.
In September 2024, Crestone, Inc. (“Crestone”) has announced positive topline results from its Phase 2 clinical trial assessing CRS3123 in patients with Clostridioides difficile infection (CDI). CRS3123 is an innovative drug candidate that has shown a narrow spectrum and minimal impact on normal gut microbiota in preclinical and Phase 1 studies. In the primary intent-to-treat (ITT) analysis, which included 43 patients, the clinical cure rates at the day 12 test-of-cure visit were similar across all treatment groups, with 28 out of 29 (97%) patients receiving one of two CRS3123 dosages, compared to 13 out of 14 (93%) in those treated with vancomycin. There were no clinical failures at the day 12 assessment, and the results for two patients were indeterminate.
In May 2024, Vedanta Biosciences administered the first dose in the Phase III RESTORATiVE303 clinical trial of VE303, a live biotherapeutic product aimed at preventing recurrent Clostridium difficile infection (rCDI). This international, double-blind, randomized, placebo-controlled study is designed to evaluate the safety and efficacy of VE303 in individuals at higher risk of rCDI following the completion of an antibiotic course for a prior infection.
In March 2024, The ongoing phase 3 trial of VE303, launched in recent months, seeks to prevent the recurrence of Clostridioides difficile infection (CDI). Known as the RESTORATiVE303 study, it aims to evaluate the safety and recurrence rates at week 8 among participants who receive either a 14-day course of VE303 or a placebo. The trial’s objectives and endpoints are identical for both Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
Clostridium Difficile Infections Overview
Clostridium difficile (C. difficile) infections, often referred to as CDI, are bacterial infections that primarily affect the digestive system. These infections typically occur when antibiotics disrupt the normal balance of bacteria in the intestines, allowing C. difficile bacteria to multiply and produce toxins that cause diarrhea and other symptoms.
Get a Free Sample PDF Report to know more about Clostridium Difficile Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight
Emerging Clostridium Difficile Infections Drugs Under Different Phases of Clinical Development Include:
ADS024: Adiso Therapeutics
DNV3837: Deinove
Ibezapolstat: Acurx Pharmaceuticals, Inc
LMN-201:Lumen Bioscience, Inc
Ridinilazole: Summit Therapeutics
CP101: Finch Therapeutics Group
SER 109: Seres Therapeutics
VE303: Vedanta Biosciences
MGB-BP-3: MGB Biopharma
CRS3123: Replidyne
Clostridium Difficile Infections Route of Administration
Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Clostridium Difficile Infections Molecule Type
Clostridium Difficile Infections Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Clostridium Difficile Infections Pipeline Therapeutics Assessment
Clostridium Difficile Infections Assessment by Product Type
Clostridium Difficile Infections By Stage and Product Type
Clostridium Difficile Infections Assessment by Route of Administration
Clostridium Difficile Infections By Stage and Route of Administration
Clostridium Difficile Infections Assessment by Molecule Type
Clostridium Difficile Infections by Stage and Molecule Type
DelveInsight’s Clostridium Difficile Infections Report covers around 22+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Clostridium Difficile Infections product details are provided in the report. Download the Clostridium Difficile Infections pipeline report to learn more about the emerging Clostridium Difficile Infections therapies
Some of the key companies in the Clostridium Difficile Infections Therapeutics Market include:
Key companies developing therapies for Clostridium Difficile Infections are – Novartis AG, Astellas Pharma, Eli Lily & Company AstraZeneca, Actelion Pharmaceuticals Ltd., Merck & Co. Inc., Baxter International Inc., Sanofi S.A, Pfizer Inc., Mylan N.V, and others.
Clostridium Difficile Infections Pipeline Analysis:
The Clostridium Difficile Infections pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
Clostridium Difficile Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Clostridium Difficile Infections drugs and therapies
Clostridium Difficile Infections Pipeline Market Drivers
Increasing cases of Clostridium Difficile Infections, increasing consumption of antibiotics are some of the important factors that are fueling the Clostridium Difficile Infections Market.
Clostridium Difficile Infections Pipeline Market Barriers
However, lack of awareness of the infection, high cost of the diagnostic and treatment of severe infection and other factors are creating obstacles in the Clostridium Difficile Infections Market growth.
Scope of Clostridium Difficile Infections Pipeline Drug Insight
Coverage: Global
Key Clostridium Difficile Infections Companies: Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others
Key Clostridium Difficile Infections Therapies: ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others
Clostridium Difficile Infections Therapeutic Assessment: Clostridium Difficile Infections current marketed and Clostridium Difficile Infections emerging therapies
Clostridium Difficile Infections Market Dynamics: Clostridium Difficile Infections market drivers and Clostridium Difficile Infections market barriers
Request for Sample PDF Report for Clostridium Difficile Infections Pipeline Assessment and clinical trials
Table of Contents
1. Clostridium Difficile Infections Report Introduction
2. Clostridium Difficile Infections Executive Summary
3. Clostridium Difficile Infections Overview
4. Clostridium Difficile Infections- Analytical Perspective In-depth Commercial Assessment
5. Clostridium Difficile Infections Pipeline Therapeutics
6. Clostridium Difficile Infections Late Stage Products (Phase II/III)
7. Clostridium Difficile Infections Mid Stage Products (Phase II)
8. Clostridium Difficile Infections Early Stage Products (Phase I)
9. Clostridium Difficile Infections Preclinical Stage Products
10. Clostridium Difficile Infections Therapeutics Assessment
11. Clostridium Difficile Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Clostridium Difficile Infections Key Companies
14. Clostridium Difficile Infections Key Products
15. Clostridium Difficile Infections Unmet Needs
16 . Clostridium Difficile Infections Market Drivers and Barriers
17. Clostridium Difficile Infections Future Perspectives and Conclusion
18. Clostridium Difficile Infections Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
